A ruling in favor of generic drugmaker Hikma will make it harder for brand-name manufacturers to block cheaper alternatives.

The trust fund for the program, which supports roughly 68 million Americans, is on schedule to be depleted in the next six years. Benefits could be cut on average by 22 percent. By Tara Siegel Bernard ...

The US Supreme Court ruled yesterday, June 4, that pharmaceutical company Hikma’s generic cardiovascular drug does not infringe global biopharmaceutical company Amarin’s patents covering its drug ...

A unanimous Supreme Court reversed the Federal Circuit and held that Amarin did not plausibly allege that Hikma’s skinny label and marketing actively induced infringement of Vascepa’s ...

Each day, millions of people pick up a prescription drug from their local pharmacy or mailbox. Most are affordable, with co-pays on average less than $7 for 90% of drugs. But for a growing number of ...

Hims & Hers Health (HIMS) on Thursday announced the launch of generic versions of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy semaglutide through its telehealth platform in Canada. The ...

The Trump administration is joining forces with Mark Cuban’s Cost Plus Drugs, Amazon Pharmacy, and GoodRx to add generic medications to the direct-to-consumer drug sales website, TrumpRx, in an ...

Dr. Reddy's Laboratories (NVO) will launch its off-patent version of Novo Nordisk’s (NVO) blockbuster GLP-1 therapy Ozempic in Canada within the “next few days,” becoming the first to sell a generic ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The day has ...

The era of cheap, officially approved semaglutide is finally here—in Canada, that is. The country has just become the first in North America and the first G7 nation to license a generic version of the ...

A Supreme Court case heard this week could give brand-name drugmakers longer monopolies, delay generic competition, and leave patients paying higher prices. When it comes to generic medications, ...

The FDA has approved the first generic versions of Farxiga, a drug used to treat Type 2 diabetes and reduce the risk of hospitalization for heart failure. The generic, dapagliflozin, is indicated to ...